Generic pain injection put to the test against Brand-Name drug

NCT ID NCT06902090

Completed Knowledge-focused Sponsor: Yangtze River Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study tests a generic version of meloxicam nanocrystal injection (a pain reliever) against the brand-name drug ANJESO® in 20 healthy adults aged 18 to 45. Researchers compare how the body absorbs and processes each drug, and check for side effects. The goal is to see if the generic version is safe and behaves similarly to the original.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: meloxicam nanocrystal injection
What this could lead to: If successful, this could show that the generic version works similarly to the brand-name drug, potentially offering a more affordable pain treatment option.
What could go wrong: This is an early-phase study with only 20 healthy people, so it cannot prove the drug works for pain. Side effects are possible, and results may not apply to patients with pain conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAIN

Contacts and locations

Locations

Sichuan Provincial People's Hospital

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.